Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Aug 21, 2018

Greg Duncan, CEO, Celtaxsys tells us about the work the company is doing to help reduce pulmonary exacerbations in patients with cystic fibrosis. Cystic fibrosis is a rare genetic life-threatening disease that affects over 70,000 people worldwide. Pulmonary exacerbations are sudden, severe respiratory events that ultimately lead to lung function decline. Celtaxsys’ lead candidate, once-daily anti-inflammatory acebilustat, which the company is currently progressing to Phase 3 development, has the potential to prevent lung function decline by reducing the frequency of pulmonary exacerbations.

#cysticfibrosis #CFresearch #RareDisease #CFAware #acebilustat

Celtaxsys.com